News
All attendees shared a vested interest in the rapidly evolving cancer treatment landscape. Nowhere was the vastness of that ...
Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...
BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...
AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...
Q4 2025 Earnings Call Transcript June 26, 2025 Aethlon Medical, Inc. beats earnings expectations. Reported EPS is $-0.40074, ...
Motor City Mile Open Water Swim Makes Waves to Fight Cancer, all proceeds go to University of Michigan cancer center.
Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.
Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...
Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...
Opdivo’s results are in contrast to Keytruda’s - In June, Merck unveiled data from its KEYNOTE-024 trial which showed its drug not only increased progression free survival, but also showed it ...
Oral cancer, which includes malignancies affecting the lips, tongue, gums, cheeks, and floor of the mouth, represents a ...
Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results